Apimeds Pharmaceuticals US (APUS) Shares Outstanding (2023 - 2025)

Apimeds Pharmaceuticals US's Shares Outstanding (Entity) history runs 3 years deep, the most recent figure standing at $12.6 million for Q4 2025.

• Quarterly Shares Outstanding (Entity) rose 59.11% year-over-year to $12.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $12.6 million (up 59.11% YoY) and the FY2025 annual result came in at $12.6 million, up 59.11% from the prior year.
• Shares Outstanding (Entity) was $12.6 million for Q4 2025 at Apimeds Pharmaceuticals US, roughly flat from $12.6 million in the prior quarter.
• Across five years, Shares Outstanding (Entity) topped out at $12.6 million in Q3 2025 and bottomed at $4.6 million in Q4 2023.
• A 3-year average of $8.8 million and a median of $7.9 million in 2024 frame the typical range for Shares Outstanding (Entity).
• Annual changes were most pronounced in 2024 — Shares Outstanding (Entity) surged 71.89% — and 2025, when it changed 0.0%.
• Apimeds Pharmaceuticals US's Shares Outstanding (Entity) stood at $4.6 million in 2023, then surged by 71.89% to $7.9 million in 2024, then soared by 59.11% to $12.6 million in 2025.
• Business Quant data shows APUS's Shares Outstanding (Entity) at $12.6 million in Q4 2025, $12.6 million in Q3 2025, and $10.4 million in Q2 2025.